-$0.32 EPS Expected for Viveve Medical Inc (VIVE) This Quarter

Equities analysts expect Viveve Medical Inc (NASDAQ:VIVE) to post earnings of ($0.32) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Viveve Medical’s earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.23). Viveve Medical reported earnings of ($0.49) per share during the same quarter last year, which suggests a positive year over year growth rate of 34.7%. The business is scheduled to report its next earnings results on Thursday, May 9th.

On average, analysts expect that Viveve Medical will report full year earnings of ($0.96) per share for the current financial year, with EPS estimates ranging from ($1.48) to ($0.77). For the next fiscal year, analysts forecast that the company will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.99) to ($0.39). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Viveve Medical.

VIVE has been the subject of several analyst reports. Maxim Group restated a “buy” rating on shares of Viveve Medical in a research note on Thursday, January 17th. Mizuho restated a “buy” rating and issued a $4.00 price objective on shares of Viveve Medical in a research note on Friday, March 15th. Finally, Craig Hallum set a $1.00 price objective on Viveve Medical and gave the stock a “hold” rating in a research note on Friday, January 18th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $4.00.

Several large investors have recently bought and sold shares of VIVE. Accredited Investors Inc. purchased a new stake in shares of Viveve Medical in the 1st quarter worth $31,000. Sargent Investment Group LLC purchased a new stake in Viveve Medical in the 4th quarter worth $32,000. Bank of New York Mellon Corp increased its stake in Viveve Medical by 266.6% in the 4th quarter. Bank of New York Mellon Corp now owns 45,223 shares of the company’s stock worth $47,000 after buying an additional 32,888 shares in the last quarter. Geode Capital Management LLC increased its stake in Viveve Medical by 13.6% in the 4th quarter. Geode Capital Management LLC now owns 216,566 shares of the company’s stock worth $227,000 after buying an additional 25,975 shares in the last quarter. Finally, RTW Investments LP increased its stake in Viveve Medical by 42.4% in the 4th quarter. RTW Investments LP now owns 4,480,565 shares of the company’s stock worth $4,705,000 after buying an additional 1,333,333 shares in the last quarter. Hedge funds and other institutional investors own 60.99% of the company’s stock.

Shares of NASDAQ:VIVE traded down $0.02 during midday trading on Wednesday, hitting $0.58. The company had a trading volume of 396,300 shares, compared to its average volume of 300,346. The company has a debt-to-equity ratio of 6.21, a current ratio of 3.89 and a quick ratio of 3.51. The firm has a market capitalization of $28.09 million, a price-to-earnings ratio of -0.36 and a beta of 0.70. Viveve Medical has a 12-month low of $0.55 and a 12-month high of $4.34.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.

Read More: Dividend

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.